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A B S T R A C T
Background: The prevalence of Fabry disease (FD) in Japanese patients presenting with unexplained left
ventricular hypertrophy (LVH) has remained unclear.
Methods: We measured plasma a-galactosidase A activity in 177 men with a diagnosis of hypertrophic
cardiomyopathy (HCM) (maximum LV wall thickness 15 mm).
Results: Two patients (1.1%) showed very low a-galactosidase A activity [0.0 and 0.3 nmol/hr/ml (normal
range: 3.6–17.6 nmol/hr/ml)], and a clinical diagnosis of cardiac variant of FD was ﬁnally made. One patient
was a 55-year-old man who came to our hospital because of abnormal results of electrocardiography
and showed concentric LVH in echocardiography. A missense mutation, R112L, was identiﬁed. The other
was a 74-year-old man who had been diagnosed with HCM at the age of 60 years in another hospital and
was referred for evaluation of repeated hospitalization for heart failure. Although echocardiography
revealed asymmetric septal hypertrophy (ASH) with interventricular septal wall thickness of 16 mm
and posterior wall thickness of 11 mm and reduced LV ejection fraction with hypokinetic posterior
wall motion, his echocardiographic ﬁndings at the initial diagnosis of HCM were not ASH but concentric
LVH with normal LV systolic function. A splicing mutation, IVS4+919G>A, was identiﬁed.
Conclusions: The prevalence of FD in Japanese male patients with a clinical diagnosis of HCM was found
to be 1.1%. These patients showed late onset and concentric LVH at initial presentation.
 2016 The Author(s). Published by Elsevier Ltd on behalf of Japanese College of Cardiology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fabry disease (FD) is an X-linked lysosomal storage disorder that
results from a deﬁciency of a-galactosidase A (a-Gal A) activity
[1,2]. This enzymatic defect leads to the progressive accumulation of
glycosphingolipids, predominantly globotriaosylceramide and glo-
botriaosylsphingosine (lyso-Gb3), throughout the body and causes* Corresponding author at: Department of Cardiology, Neurology and Aging
Science, Kochi Medical School, Kochi University, Oko-cho, Nankoku-shi, Kochi 783-
8505, Japan. Tel.: +81 88 880 2352; fax: +81 88 880 2349.
E-mail address: jm-kubotoru@kochi-u.ac.jp (T. Kubo).
http://dx.doi.org/10.1016/j.jjcc.2016.05.014
0914-5087/ 2016 The Author(s). Published by Elsevier Ltd on behalf of Japanese College
creativecommons.org/licenses/by-nc-nd/4.0/).multisystemic problems including neurological, ocular, skin, renal,
and cardiac manifestations in classic type of FD. The majority of
patients with this disease have cardiac involvement that is mainly
manifested as left ventricular hypertrophy (LVH). Since Nakao et al.
reported a 3% prevalence of an atypical variant of FD in male patients
with LVH [3], a cardiac variant of FD with late-onset isolated cardiac
manifestation has been recognized. Cardiac involvement of FD is
associated with signiﬁcant morbidity and early death due to heart
failure or ventricular arrhythmias [1,4]. Since disease-speciﬁc
enzyme replacement therapy (ERT) is now available for FD, correct
diagnosis is important [5–7]. However, there has been no report
since the report by Nakao et al. on the prevalence of FD in Japanese
patients presenting with unexplained LVH. of Cardiology. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Clinical characteristics of study patients.
HCM (n = 177)
Age at the study (years) 62  13 (15–87)
Age at diagnosis of HCM (years) 56  14 (15–87)
Maximum LV wall thickness (mm) 19  4 (10–33)
Interventricular septal wall thickness (mm) 15  4 (7–29)
Posterior wall thickness (mm) 12  2 (7–23)
LV end-diastolic diameter (mm) 48  6 (32–69)
LV end-systolic diameter (mm) 29  7 (16–56)
Fractional shortening (%) 40  9 (15–59)
Left atrial diameter (mm) 45  7 (30–69)































Fig. 1. The distribution of plasma a-galactosidase A activity across all subjects in the
study.
T. Kubo et al. / Journal of Cardiology 69 (2017) 302–307 303The aim of this study is to determine the prevalence of FD in a
Japanese cohort of male patients with a clinical diagnosis of
hypertrophic cardiomyopathy (HCM) by using a-Gal A screening.
Methods
Subjects
We performed clinical evaluation including measurements of
plasma a-Gal A activity in 177 consecutive unrelated male patients
with HCM between May 2003 and March 2014.
The diagnosis of HCM was based on echocardiographic
demonstration of unexplained LVH, i.e. maximum LV wall
thickness  15 mm. Patients with the dilated phase of HCM who
showed previous documentation of unexplained LVH by echocar-
diography (maximum LV wall thickness  15 mm) were included
in this study. Informed consent was obtained from all patients or
their parents in accordance with the guidelines of the Ethics
Committee on Medical Research of Kochi Medical School (approval
number: 14-34).
Clinical evaluation
Evaluation of patients included medical history, clinical
examination, 12-lead electrocardiography, and M-mode, two-
dimensional (2-D) and Doppler echocardiography. Maximum LV
wall thickness was deﬁned as the greatest thickness in any single
segment. Left ventricular end-diastolic diameter (LVEDD) and end-
systolic diameter (LVESD) were measured from M-mode and 2-D
images obtained from parasternal long-axis views, and fractional
shortening [%FS = (LVEDD  LVESD)/LVEDD  100] was calculated.
Measurements of a-Gal A and lyso-Gb3
Peripheral venous blood samples were collected from all of the
patients for measurement of plasmaa-Gal A activity. The activity was
determined using the method previously described at Kagoshima
University [3]. The normal range was 3.6–17.6 nmol/hr/ml.
We measured lyso-Gb3 in plasma samples from two patients
with low a-Gal A activity. The measurement of lyso-Gb3 was
carried out by high-performance liquid chromatography (HPLC)
according to the method described previously [8]. The normal
range was <2 nmol/l.
Genetic analysis
We performed genetic analysis for the two patients with low a-
Gal A activity. Peripheral blood samples were taken, and they were
frozen and stored at 20 8C. Deoxyribonucleic acid (DNA) was
extracted and in vitro ampliﬁcation of genomic DNA was performed
using polymerase chain reaction (PCR) as previously described.
Oligonucleotide primers were used to amplify exons (exon 1 to exon
7) and the middle of intron 4 for speciﬁc splicing defect mutation
(IVS4+919G>A) of the GLA gene. Information on primer sequences
and PCR conditions is available upon request. Sequencing was
performed using a BigDye Terminator Cycle Sequencing Kit from
Applied Biosystems Inc. (Waltham, MA, USA), and the sequences
were analyzed on an Applied Biosystems PRISM 3100-Avant Genetic
Analyzer in accordance with the manual of the manufacturer.
Results
Clinical characteristics of study population
We studied 177 men with a clinical diagnosis of HCM. Table 1
shows the clinical characteristics of the HCM patients in thepresent study. The patients were aged from 15 to 87 years (mean
age, 62  13 years) and the mean age at diagnosis of HCM was
56  14 years. Maximum LV wall thickness was 19  4 mm.
Patients with FD
Fig. 1 shows the distribution of plasma a-Gal A activity across
all the subjects in the study. We found very low plasma a-Gal A
activity in two patients (1.1%) [0.0 and 0.3 nmol/hr/ml (normal
range: 3.6–17.6 nmol/hr/ml)] and a clinical diagnosis of cardiac
variant of FD was ﬁnally made. The clinical characteristics of these
two patients and the results of genetic analysis are shown in
Table 2. The mutations we identiﬁed were absent in at least
100 healthy individuals.
One patient (Patient no. 1) was a 55-year-old man who came to
our hospital because of abnormal results of electrocardiography
conducted by a group medical examination. He had no history of
any symptoms or diseases. Electrocardiography showed LVH with
ST-T change and a relatively short PR interval of 133 ms (Fig. 2a).
He had no symptoms and showed concentric LVH with wall
thickness of 18 mm in echocardiography (Fig. 2b). Cardiovascular
magnetic resonance (CMR) imaging revealed concentric hypertro-
phy with late gadolinium enhancement in the basal lateral wall
(Fig. 2c). Fig. 2d shows the pathology of a skin biopsy. Electron-
microscopic ﬁndings in the skin lesion showed the characteristic
lamelatted dense bodies in the endothelial cells at the dermis.
Plasma lyso-Gb3 level was high and missense mutation R112L was
Table 2
Clinical characteristics and genetic results in patients with Fabry disease.
Patient no. 1 Patient no. 2
Plasma a-Gal A activity (nmol/hr/ml) 0.0 0.3
Lyso-Gb3 (nmol/l) 5.0 <2.0
Age at the study (years) 55 74
Age at diagnosis of HCM (years) 55 60
NYHA functional class at the study I III
Atrial ﬁbrillation at the study + –
Echocardiographic ﬁndings at the study
Interventricular wall thickness (mm) 17 16
Posterior wall thickness (mm) 16 11
LV end-diastolic diameter (mm) 36 47
LV end-systolic diameter (mm) 23 35





Corneal opacities NA –
Proteinuria – –
Cerebral infarction – –
Genetic analysis R112L IVS+919G>A
a-Gal A, a-galactosidase A activity; HCM, hypertrophic cardiomyopathy; LV,
left ventricular; NA, not available; NYHA, New York Heart Association
functional class; Lyso-Gb3, globotriaosylsphingosine.
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the basis of reports of three other disease-causing substitutions in
the same codon (R112C, R112H and R112S) [9–11]. His family tree
is shown in Fig. 2e. Although he had mild hypohidrosis, his clinical
manifestation was mainly limited to the heart. After 5 years of ERT,
the degree of LVH had not changed signiﬁcantly.
The other patient (Patient no. 2) was a 74-year-old man who
had been diagnosed with HCM at the age of 60 years in another
hospital and was referred for evaluation of repeated hospitaliza-
tion for heart failure [12]. Electrocardiography showed complete
left bundle branch block and normal PR interval of 187 ms (Fig. 3a).
Although echocardiography revealed asymmetric septal hypertro-
phy (ASH) with interventricular septal wall thickness of 16 mm
and posterior wall thickness of 11 mm and reduced LV ejection
fraction with predominantly hypokinetic wall motion of the
posterior region (Fig. 3b), his echocardiographic ﬁndings at initial
diagnosis of HCM in the previous hospital were not ASH but
concentric LVH with interventricular septal wall thickness and
posterior wall thickness of 16 mm and normal LV systolic function
(Fig. 3c). There was no typical pathology of FD from a skin biopsy,
and his plasma lyso-Gb3 level was below the detection level
(<2 nmol/l) and it could not be differentiated from the normal
controls. However, genetic analysis revealed an intronic mutation
(IVS4+919G>A) that is known to be a Chinese hot spot mutation
causing late-onset variant of FD with cardiac hypertrophy in
Taiwan [13,14]. He was ﬁnally diagnosed as having advanced stage
of a cardiac variant FD. His family tree is shown in Fig. 2e. During
ERT for about 2 years, he had repeated hospitalization for heart
failure, and sudden cardiac death occurred at home.
Discussion
Our study shows a 1.1% prevalence of FD in a Japanese cohort of
male patients with a clinical diagnosis of HCM. Our results were
different from the study by Nakao et al. (3% prevalence of an
atypical variant of FD in male patients with cardiac hypertrophy)
[3]. We speculate the reason why there is the different prevalence
of FD in patients with LVH between these two studies. First, the
cut-off value of LV wall thickness on echocardiography was
different between Nakao’s report and our current study: Nakao
et al. screened the enzyme activity in patients with LVH (LVH wasdeﬁned as LV wall thickness more than or equal to 13 mm on
echocardiography) and our study cohort included patients with
diagnosis of HCM who showed LV wall thickness 15 mm on
echocardiography [3]. Second, Nakao et al. identiﬁed seven
patients with cardiac FD in 230 male patients with LVH, and their
subsequent genetic study revealed that four of these seven patients
had identical intronic mutation (IVS4+919G>A) that was the same
as the mutation we identiﬁed in patient no. 2 (he is originally from
Kagoshima prefecture) in our study [3,13]. From these results, this
intronic abnormality (IVS4+919G>A) might be a hot spot mutation
causing cardiac variant of FD in the Kagoshima area. Although
there have been several reports on the prevalence of FD in patients
with HCM in various cohorts and with several screening methods
in Western countries, our data are consistent with results of recent
studies with larger numbers of patients by means of screening
based on low plasma enzymatic activity [3,15–18]. Monserrat et al.
reported that they screened plasma a-Gal A activity in 328 unre-
lated male patients with HCM and found a prevalence of FD of 0.9%
[17]. Hagege et al. performed systematic screening for FD in
patients with a diagnosis of HCM by an a-Gal A assay on dried
blood spots using a ﬁlter paper test and they identiﬁed four FD
patients out of 278 men (1.4%) [18].
The two patients with FD we identiﬁed were clinically
diagnosed as having a cardiac variant of FD. Although the patient
with R112L mutation showed almost zero a-Gal A activity, FD
manifestations other than cardiac hypertrophy were not notice-
able. The patient with IVS4+919G>A mutation had slight residual
a-Gal A activity, and this intronic mutation is known to be a
popular mutation causing a cardiac variant form in Taiwan
[19]. These two patients showed cardiac hypertrophy after middle
age as their clinically initial manifestations and they both showed
concentric LVH at the initial diagnosis of HCM, as a generally
reported cardiac manifestation. In the present study, the patient
with IVS4+919G>A mutation showed ASH with reduced LV
ejection fraction on echocardiography at the initial visit to our
hospital, but a review of his echocardiographic data at his initial
diagnosis of HCM in the previous hospital revealed that he had not
ASH but concentric LVH with normal LV systolic function.
Takenaka et al. reported that patients with terminal stage cardiac
manifestations of FD showed hypokinesis with thinning of the base
of the LV posterior wall [4]. Their histologic studies revealed that
FD patients had sarcoplasmic vacuolization and deciduation of
myocardial cells with fatty inﬁltration and diffuse ﬁbrosis of the
stroma in the left ventricle, and the thinned region showed marked
ﬁbrosis with almost no myocardial cells. Although ASH is the most
common type of morphologic pattern and is often used as a
synonym of HCM, it is important to recognize that LV wall thinning
limited to the LV basal posterior wall seen in the advanced stage of
FD may lead to this morphology. Although there are several
hypotheses that myocardial ﬁbrosis develops in cardiomyopathies
[20,21], the mechanisms why the localized thinning occurs at the
base of the LV posterior wall remain unclear. Several electrocar-
diographic characteristics have been reported to appear early in
the course of FD, including both a short PR interval and prolonged
PR interval [22–24]. Some early reports on FD showed a shortened
PR interval and its usefulness for detecting cardiac involvement in
FD [22,23]. On the other hand, Niemann et al. reported that a short
PR interval (<120 ms) was not relevant (16%) in their large cohort
of patients with untreated FD in all stages of cardiomyopathy [25].
In the patients with FD in our study who received ERT for
several years, there has been no remarkable improvement in
myocardial morphology or function. Weidemann et al. reported
results of long-term observation to evaluate the impact of ERT on
Fabry cardiomyopathy in relation to baseline disease stages
[26]. They found that patients with myocardial ﬁbrosis in contrast
to these without ﬁbrosis assessed by the magnetic resonance
Fig. 2. (a) Electrocardiography in patient no. 1. (b) Echocardiography in patient no. 1: parasternal long-axis view (end-diastole). (c) Late gadolinium enhancement imaging in
cardiovascular magnetic resonance in patient no. 1. (d) Electron microscopic ﬁndings in the biopsied skin tissue in patient no. 1. (e) Family tree of patients no. 1 and 2.
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myocardial function or exercise capacity. Patients who show
maximum LV wall thickness  15 mm (general diagnostic criteri-
on for HCM) are likely to have regional myocardial ﬁbrosis. In our
case, Patient no. 1 showed concentric LVH with wall thickness of18 mm in echocardiography and high intensity lateral wall scar in
CMR imaging. Although treatment of FD with ERT should be started
before myocardial ﬁbrosis has developed, we need to clarify
whether ERT is still effective for patients with prominent LVH or
myocardial ﬁbrosis with regard to prevention of deterioration of
Fig. 3. (a) Electrocardiography in patient no. 2. (b) Echocardiography in patient no. 2 at the age of 74 years at initial presentation in our hospital: parasternal long-axis view
(end-diastole). (c) Echocardiography in patient no. 2 at the age of 60 years at initial diagnosis of hypertrophic cardiomyopathy in the previous hospital: parasternal long-axis
view (end-diastole).
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HCM patients is important in that it allows identiﬁcation of disease
carriers in relatives, particularly younger carriers.
In our study, we focused on screening for FD using measure-
ment of a-Gal A activity in a cohort of male patients. For
heterozygous females, a-Gal A screening is not sufﬁcient to
identify patients with FD because female patients show a wide
range of a-Gal A activity overlapping that in normal healthy
people. Lyso-Gb3 has recently been shown to be a biomarker of FD
and it has been reported to have high diagnostic sensitivity for an
atypical variant of FD in males with residual a-Gal A activity.
However, the patient with IVS+919G>A mutation in our study
showed undetectable level of lyso-Gb3, and Liu et al. reported that
lyso-Gb3 might not be a reliable biomarker for monitoring the
long-term therapeutic outcomes of ERT for late-onset FD patients
with the same mutation (IVS+919G>A) [14]. Recently a high-
sensitive assay method for measuring lyso-Gb3 in clinical samples
by means of nano-liquid chromatography-tandem mass spectrom-
etry has been developed, and it enables us to determine low level of
plasma lyso-Gb3 concentration [27]. An application of this novel
assay system will be useful for diagnosis of cases with unknown
clinical signiﬁcance and for monitoring the efﬁcacy of ERT.There are several limitations in this study. First, the number in
the cohort was relatively small and the data were from a single
center in a rural area. Therefore, a further study based on a large
and multicenter cohort in Japan is needed. Second, we were not
able to evaluate the pathology of endomyocardial biopsy in two
patients with cardiac variant of FD.
Conclusions
By means of screening based on low a-Gal A activity, the
prevalence of FD in Japanese male patients with a clinical diagnosis
of HCM was found to be 1.1%. These patients were diagnosed as
having a cardiac variant of FD and showed late onset and
concentric LVH at initial presentation.
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